Results

Pardes Biosciences Inc.

02/14/2022 | Press release | Distributed by Public on 02/14/2022 06:33

Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at[...]